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The use of hyaluronic acid based dressings to treat 
burns: A review
Introduction
Deep cutaneous acute lesions, such as burns, traumas or 
ulcers, are all conditions characterized by a massive loss of  
dermis; therefore the restoration of  a full-thickness dermal 
layer is of  primary importance to start the healing process. 
Once a proper dermal bed has been well developed, wound 
closure is facilitated spontaneously or by applying a skin 
graft. Nevertheless, immediate coverage with autologous 
skin is not always available or possible. In these cases, 
alternative solutions may be taken into considerations to 
favor an adequate repair and effective functional recovery 
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of  the burned area. Hyalosafe and Hyalomatrix (Anika 
Therapeutics s.r.l., Abano Terme, Italy) are medical devices 
based on hyaluronic acid (HA) derivatives that have been 
developed for this purpose.
Here in this monograph a narrative describing the applica-
tion of  the HA ester technology for the development of  
treatments for acute lesions, specifically burns, and the 
correspondent clinical results is presented.
Acute lesions are those which are not associated to a healing 
defect and that usually occur secondarily to a surgery or a 
trauma in a healthy individual. In these cases, the lesion 
may be deep and cause injury to muscles, blood vessels, 
nerves, bones and involve other body parts as well. It may 
also lead to severe loss of  blood and tissues. Deep wounds 
that completely destroy the epidermis and part of  the dermis 
have functional impacts as well, such as the impairment of  
skin oxygenation and effects on the tissue healing ability. 
Consequences can be very severe in terms of  fluid manage-
A B S T R A C T
Deep cutaneous lesions such as burns, traumas or ulcers are all conditions characterized by a massive loss of dermis, bringing 
several important consequences. For the treatment of these conditions, the evolution of material science has made available new 
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ment with the possibility of  leading to dehydration and 
shock. Protein loss can also be serious, as well as the risk 
of  contracting infections. To avoid all these dramatic con-
sequences, prompt wound covering is an essential measure 
to be taken.[1] Standard clinical procedure comprises early 
escharectomy, followed by immediate tissue reconstruction 
with a skin graft.[2,3] This protocol represents the optimal 
solution for decreasing the risks related to wound infection, 
scar formation and excessive fluid loss and also allows the 
reduction of  patient hospitalization time. In this light, the 
gold standard is represented by the use of  autologous skin 
to cover the injury; nevertheless an immediate coverage 
with autologous skin in deep and extensive burns is not 
always possible. In these cases, alternative solutions have 
to be taken into considerations. For example, the grafting 
of  cryopreserved, whole cadaver skin is a possible option 
to consider when autograft is not feasible, but problems re-
lated to availability and risk of  viral transmission represent 
limitations for this technique.
Therefore, synthetic alternatives like dermal substitutes 
and advanced wound dressings have been designed and 
proposed for specific clinical use in burns.
Dermal substitutes are generally preferred in full-thickness 
lesions (such as traumas, surgical wounds, chronic ulcers, 
etc.) and have been shown to minimize hypertrophic scar-
ring, contractures and increase scar elasticity in acute burn 
wounds.
On the other side, for the treatment of  first and superficial 
second degree burns, affecting the epidermis and the su-
perficial dermis, advanced wound dressing have been real-
ized in order to promote wound healing by facilitating cell 
migration and proliferation and growth factor release.[4-6]
A variety of  biomaterials for medical applications has 
been designed and developed in recent years and large 
efforts have been dedicated to the development of  new 
biocompatible and biodegradable polymers which should 
release safe degradation products that enter into the nor-
mal metabolic pathway. Many advanced wound dressings 
consist of  biomaterials made from various components of  
the extracellular matrix (ECM) and are theorized to favor 
healing by providing a structural scaffold and the signals 
important to complex cellular interactions during the 
healing phases. Among a series of  possible materials, HA 
chemistry represents an interesting and valuable option 
for the development of  medical devices for epidermal and 
dermal wound treatment.
Hyaluronic acid based materials
The scientific rationale for the development of  bioma-
terials based on HA relies on the characteristics of  the 
material, which is a structural component of  the ECM 
architecture and has an important role in water homeo-
stasis that could favor tissue hydration, which is conducive 
to wound healing.
HA is an important polysaccharide components of  the 
ECM and it is also plentiful in embryonic mesenchymal 
tissues. It is among the most hygroscopic natural molecules; 
when absorbing water, HA molecules can swell in volume 
up to 1000 times, forming loose hydrated matrices.[7] Prob-
ably, this character is the main cause behind many of  its 
biological properties. The viscoelasticity of  HA provides 
lubricating properties and shock-absorbing properties, that 
make it essential for the synovial fluid and the vitreous 
humor in the eye. Because of  their high hygroscopicity, 
the solutions of  HA are extremely osmotic, which is more 
significant in the presence of  serum albumin, as is the case 
in most tissue fluids. In skin tissues, this is a key feature 
in regulating tissue hydration, especially in changing pe-
riods such as embryonic development, or during inflam-
matory processes after tissue damage, when the levels of  
HA are increased. Hyaluronan, or its acid form HA, is 
a polymer of  disaccharides composed of  D-glucuronic 
acid and D-N-acetylglucosamine, linked via alternating 
β-1,4 and β-1,3 glycosidic bonds. Hyaluronan can have 
up to 25,000 disaccharide repeat units in length and range 
in size approximately from 5,000–20,000,000 Da in vivo. 
Depending on the different molecular weights of  the HA 
molecule, HA has been observed to play different roles in 
the body. Considering exogenous HA, the high molecular 
weight properties are related to angiogenesis inhibition 
and to a mostly physical role, while low molecular weight 
HA has been associated with a modulating effect on the 
inflammatory process due to its action on free radicals,[8-10] 
its antioxidant action[11] and by excluding lithic enzymes 
from the immediate cellular environment and other extra-
cellular matrix components.[8,12] This moderating action 
can contribute to the stabilization of  granulation tissue 
matrix, which is rich in HA.[13,14] In fact, even if  inflam-
mation is part of  granulation tissue formation, it needs to 
be modulated in the normal tissue healing process. The 
process by which HA fragments promote granulation tis-
sue formation is complicated and has been associated to 
superior collagen deposition.[15]
Endogenous HA plays several architectural roles in the extra 
cellular matrix (ECM) organization by binding with cells 
and other components through specific and non-specific 
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links. HA specifically interacts with several proteoglycans 
(such as aggrecan, versican) through HA-binding motifs and 
organizes the networks of  fibrin, fibronectin and collagen.[7]
The HA molecule has been shown to contribute as a 
modulator of  many of  the biological processes thanks 
both to its physicochemical and biological characteristics. 
For example, it has been reported that high tissue concen-
trations of  HA are present during the activation of  key 
biological processes such as remodelling, regeneration and 
morphogenesis.
Interestingly, HA is involved in the early stages of  tissue 
repair and wound healing being, together with fibrin, a 
component of  the matrix which forms to aid fibroblast and 
endothelial cell organization into the injury site. Specifically, 
HA hydrophilic properties make the fibrin clot softer and 
easier for the cells to colonize. These cellular processes are 
essential steps to allow progress of  the tissue regeneration 
process as they allow the structural construction of  the 
newly-forming tissue.[16,17]
Additionally, HA plays a definite role in controlling the 
angiogenic process. This modulation role is driven by the 
molecular weight. In fact, it has been demonstrated that 
high molecular weight-HA is an inhibitor of  angiogenesis[18]
and exerts a predominantly architectural role while, on the 
other hand, the oligosaccharides of  low molecular weight-
HA have shown a marked angiogenic effect in a series of  
experimental models,[19-21] besides stimulating collagen 
production in endothelial cells.[22]
In order to develop appropriate regenerative medicine 
strategies, fetal wound healing has been studied as an ideal 
tissue healing condition as it is characterized by the lack of  
fibrotic scar formation. Remarkably, a prolonged presence 
of  HA has been reported to be associated to the scarless fetal 
tissue repair,[23-26] and in relation to this observation, some 
authors proposed that a HA rich environment inhibits the 
matrix cells responsible for scar formation.[27,28]
Considering the specific issue of  skin wound and healing, 
the use of  HA as starting polymer to develop a medical 
material is suggested by the role that the molecule plays 
in normal epidermis, where it is found in relatively high 
concentration in the basal layer.[29,30] In this tissue HA main 
functions are related to the extracellular space 3-dimen-
sional architecture, to the structure hydration for nutrient 
flow and to the involvement in keratinocyte proliferation 
and migration.[31] For all of  the above described reasons, 
exogenous HA has been investigated in wound healing 
applications and the results coming from those studies 
demonstrated that HA is effective even in challenging 
conditions such as chronic wounds. In vivo preliminary 
experiments designed to characterize HA’s role in heal-
ing of  different tissues demonstrate that topically applied 
HA is able to favor skin wound healing in rats[32,33] and 
hamsters[34] and perforated tympanic membrane healing 
in rats.[35]
Nevertheless, poor physical properties of  this natural 
polymer (that is short residence time in vivo and solubility) 
represent a serious limitation for its direct use in the medi-
cal field.[36] Methods of  chemical modification of  natural 
polymers have been applied to HA to produce a material 
with enhanced resistance to degradation and therefore 
longer residence time and physical and chemical proper-
ties that allows for multiple manufacturing processes.[37] 
Clinical experience with hyaluronic acid based dressings 
to treat burns
HYAFF® 11 is a HA derivative polymer obtained by the 
esterification of  the free carboxylic group of  glucuronic 
acid with benzylic alcohol with the aim of  improving the 
polymer stability, while maintaining the biological and 
safety characteristics of  the starting molecule.[38] This 
chemical modification decreases the hydrophilic carboxyl 
groups and increases the hydrophobic components of  the 
polysaccharide. Upon esterification, the obtained bio-
polymer can be processed to manufacture materials with 
several types of  physical conformations, therefore suitable 
for a wide range of  clinical applications. The chemical 
process allows control over the percentage of  esterification, 
which has found to be correlated to solubility properties. 
HYAFF® 11 degradation has been studied and described 
through dedicated experiments and it has been observed 
that the material is undergoing hydrolytic degradation of  
the ester bond, conducting to a gradual de-esterification 
of  the polymer which is then increasingly hydrated, be-
coming more similar to native HA.[38] In vivo data have 
confirmed the biocompatibility of  the biomaterial and its 
safe degradation through a well-known metabolic pathway.
Recently, the use of  different HA derivatives in healing 
burns and epithelial surgical and chronic wounds has been 
evaluated with a systematic review of  the literature and a 
meta-analysis taking into account relevant randomized 
controlled trials. A positive effect of  HA in the healing of  
chronic wound ulcers of  various etiologies, burns and epi-
thelial surgical wounds was observed no matter the form in 
which HA is delivered, showing that HA derivatives favor 
the healing process.[39] The results of  the analysis performed 
additionally pointed out that HA derivatives significantly 
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improved the healing of  wounds versus traditional stan-
dards of  care.
Hyalomatrix and Hyalosafe are HA based medical devices 
dedicated to wound healing that have been designed, 
developed and manufactured using HYAFF® 11 tech-
nology. During their design and development process, 
the main requirements considered were the need of  
providing a temporary coverage for the wound via an 
off-the-shelf  approach, the possibility of  facilitating the 
healing process and specifically the dermal regeneration 
and biological safety of  the overall approach. Moreover 
the ease of  use and affordability were also considered as 
important points.
HA based dermal substitute use in burn treatment 
Hyalomatrix is a bi-layered, sterile, flexible and conformable 
dermal substitute designed to provide immediate wound 
closure and to promote the permanent regeneration of  
dermis [Figure 1]. The layer in contact with the wound is 
a 3D fibrous matrix made of  HYAFF® 11, while the top 
layer is a thin and transparent silicone membrane. The 
HYAFF® fibrous matrix layer, once in contact with the 
wound bed, integrates and starts the release of  HA. This 
biodegradable matrix acts as a scaffold for cellular invasion, 
dermal matrix component deposition and organization and 
capillary growth, while stimulating dermal (fibroblasts) 
and vascular (endothelial) cells organization at the wound 
site.[2,40-42] Following spontaneous degradation through the 
de-esterification process, the HYAFF® fibers release HA 
in a prolonged manner,[41] which favors epidermal cells 
migration allowing a spontaneous re-epithelization from 
the wound margins. These actions lead to new dermal 
tissue reconstruction and, in many cases, to spontaneous 
re-epithelization. On the outer side, the thin silicone layer 
protects the wound from external contaminations and 
prevents excessive fluid loss. Moreover, being transparent, it 
allows continuous monitoring of  the wound healing process 
without dressing removal. The silicone layer is designed 
to be easily removed without pain or wound bed damage 
following the formation of  the neo-tissue.
Hyalomatrix is currently indicated for clinical use as a 
dermal substitute for the immediate coverage, following 
surgical excision and prior to grafting, of  deep burns and 
partial to full-thickness post-traumatic, post-surgical or 
deep-chronic wounds, such as vascular ulcers and diabetic 
foot ulcers. In recent years, clinical evidence has been col-
lected and published to report the result of  the treatment 
with Hyalomatrix in this application field.
Subsequently Gravante et al. and Osti, published larger 
clinical experiences on the use of  Hyalomatrix in acute 
wounds such as burns.[43,44]
A multicenter retrospective national survey (2005-2006) 
involving 11 burn care centers, 57 patients, with deep partial 
(n = 31, 54.4%) and full thickness burns (n = 22, 38.6%) was 
performed. Mean follow-up was 37 days (range 1-472 days). 
Cleansing/debridement was conducted in 42.1% of  cases 
(n = 24), dermabrasion in 28.1% (n = 16), escharectomy in 
26.3% (n = 15), then Hyalomatrix was applied. A total of  
53.6% (30/56) of  cases underwent grafting.[43]
On day 7 after the use of  Hyalomatrix, reepithelization was 
observed more frequently in deep partial thickness than in 
full thickness burns, while no significant differences between 
adults and young patients were reported. After 29 days 
(second evaluation), almost all patients were present and 
complete closure was achieved in 32.7% of  patients. At the 
last evaluation, complete closure of  the wound was achieved 
in 85.7% of  presented patients (28/57), with 14.3% (n = 4) 
still having a partial reepithelization. No differences were 
observed for burn depth or patients undergoing grafting, 
while the Vancouver Scar Scale showed better values for 
adults. Receiving graft is more frequent in adults (69.6%) 
than young patients (47.4%). Thus, Hyalomatrix has been 
applied to young and adults, in deep partial and full thick-
ness burns, either temporarily as wound coverage before 
grafting or alone for wound healing.[43] No adverse reactions 
have been reported. The study outcomes demonstrate that 
Hyalomatrix is good in safety profile, and effective as a skin 
regenerative matrix.
The skin pH variation from the acute phase to the epithe-
lialization was observed in a burn patient that was first 
medicated with a hydrogel, Burnshield (Levtrade Inter-
Figure 1: Hyalomatrix is a bi-layered dermal substitute. In this picture the 
HYAFF® 11 layer is in the front, while the back side is the silicone layer.
Longinotti: HA based dressings in acute lesions
Burns & Trauma • October 2014 • Vol 2 • Issue 4 166
national (Pty) Ltd) and then treated with Hyalomatrix 
until complete epithelialization.[44] The pH was measured 
from day 1 post-burn and every other day, thereafter until 
complete re-epithelialization. Alkaline pH values were 
found for the burned skin from the day of  the burn until 
day 12, with an alkaline pH peak on day 4; the values 
then gradually returned to normal (pH, 5.5) from day 
13 onwards.
As pediatric patients are a large and significant population 
in burn treatment, specific studies were carried out to evalu-
ate the Hyalomatrix administration in this group.
With specific reference to pediatric patients, a study on 300 
subjects was performed using Hyalomatrix as a temporary 
dermal substitute to cover deep partial-thickness burns after 
dermabrasion.[45,46] The dermabrasion technique followed 
by coverage of  the treated area, in fact, did improve the 
prognosis of  burns victims and the correspondent aesthetic 
and functional outcomes, especially in the pediatric patient 
population.[46,47] This intermediate step with Hyalomatrix 
treatment was introduced in order to remove necrotic debris 
and to stimulate tissue regeneration in a wet and protected 
environment. In this study, 83% of  patients had healing 
within day 21, indicating that the application of  Hyaloma-
trix after dermabrasion is a useful and feasible approach 
for the treatment of  deep partial-thickness burns. Some 
kind of  hypertrophic processes were observed in almost all 
patients during the first year, however in 90% of  the cases, 
hypertrophic scars disappeared within 1 year, and in 96% 
in 2 years. Only 4% of  cases (n = 12) had hypertrophic 
scars that lasted for more than 2 years requiring treatment 
with intralesional corticosteroids injections. Additionally, 
the incidence of  infection was investigated in comparison 
to the historical data within the same center, indicating a 
decrease of  their occurrence to 10%, as compared to the 
historical results of  29.5%.
An additional experience with the clinical use of  Hya-
lomatrix was reported in the case of  tendon exposure 
and loss of  substance following burns, trauma or chronic 
injuries.[48] In the study, 30 patients underwent surgical 
debridement followed by autologous platelet-rich plasma 
(PRP) gel injection. PRP may be injected intralesionally, 
intratendonally or perilesionally, or mixed with autologous 
thrombin in a 9:1 ratio forming a platelet gel; the wounds 
were then covered with Hyalomatrix. The severity of  open 
wounds was noticeably reduced after treatment with PRP 
and the HA matrix — only one patient needed a free 
flap to cover exposed bone and tendon. Based on these 
results and the ones from previous studies, it is suggested 
that using PRP and the HA matrix together significantly 
enhances the formation of  granulation tissue and helps 
prevent infection.[49]
A series of  10 cases was also reported in which loss of  
substance due to trauma, tumor or third-deep burns (n = 5) 
was treated with Hyalomatrix, followed by a thin skin 
graft.[50] Good efficacy was reported in the short term and 
at 12 months. A flexible skin equivalent to that observed 
with collagen acellular dermal substitute as well as lack 
of  adhesion of  the tendon graft skin was observed which 
confirmed the dermal regeneration.
In summary, Hyalomatrix is a bilayered device, comprised 
of  a wound contacting scaffold-like material and a semi-
permeable silicone membrane. It is an advanced wound 
dressing that can be readily used as a skin substitute for 
wound coverage, following the surgical preparation of  
the wound and before grafting in burn patients. In second 
degree burns, after the removal of  necrotic tissues, it can 
be used to protect the residual dermal layer and may also 
stimulate the reepithelization from the wound edge and skin 
appendages. Contrarily, in full thickness burns and cases 
that can’t undergo skin grafting immediately, Hyalomatrix 
can be used as a temporarily treatment after the wound 
cleaning for wound bed protection prior to the definitive 
treatment of  skin grafts or other procedures such as cultured 
autologous keratinocytes.
HA film wound dressing in burn treatment
Using the same HYAFF® 11 technology, another product, 
named Hyalosafe, was designed and developed to provide 
effective coverage for superficial wounds. Hyalosafe is a 
transparent film wound dressing [Figure 2] indicated for 
use in the treatment of  first and superficial second-degree 
burns. The use of  the product in deep partial thickness burns 
in pediatric patients to cover the burn at recovery, prior to 
dermabrasion has also been reported.[51]
Figure 2: Hyalosafe is a transparent fi lm wound dressing.
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The HYAFF® 11 film is applied directly on the lesion, 
keeping the wound moist and thus creating the ideal 
conditions for a rapid re-epithelialization, avoiding the 
risk of  tissue maceration. Thanks to the release of  hyal-
uronic acid during HYAFF® 11 degradation, Hyalosafe 
interacts with the lesion environment, facilitating the 
renewal of  the epithelium. Importantly, as this membrane 
does not adhere to the wound, its removal is painless for 
the patient.
The use of  HYAFF® 11 film in the treatment of  second- 
degree face burns[52] has been reported on 40 children. 
Face burns are an important problem which often requires 
hospitalization and represent 25% of  the overall extensive 
pediatric burns. This type of  burns is related to an important 
fluid loss due to the characteristics of  the affected tissue. In 
general, epidermal and superficial dermal wound have the 
ability to recover without scarring in absence of  infections, 
therefore there is a strong need for treatments that are able to 
protect the burned area. Hyalosafe was used for this purpose 
showing very good healing properties and leading to notable 
aesthetic results. No case of  wound infection was reported.
Conclusion
In conclusion, important tools based on HA biopolymers 
are now available for the treatment of  acute wounds, such 
as burns. These biomaterials have been designed and de-
veloped to realize advanced dressings able to protect the 
wound and facilitate healing combining the properties of  
HA and the improved characteristics of  the ester derivatives 
which assure long term residence time and processibility.
This class of  devices represents a valuable clinical option 
for burn management as confirmed by the current clinical 
experience with Hyalomatrix and Hyalosafe.
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